BioTuesdays

Author - Stephen Kilmer

Point Biopharma Logo
Markets

WB starts POINT Biopharma at outperform

William Blair initiated coverage of POINT Biopharma Global (NASDAQ:PNT) with an “outperform” rating based on a view that the Street is “underestimating the clinical and commercial potential of the company’s...

July 6, 2022
Theseus Logo
Markets

HCW starts Theseus Pharma at buy; PT $22

H.C. Wainwright launched coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with a “buy” rating and price target of $22. The stock closed at $5.20 on June 29. “We believe pan-inhibition could be the key to success in...

June 30, 2022
Acumen Pharmaceuticals Logo
Markets

HCW starts Acumen Pharma at buy; PT $15

H.C. Wainwright initiated coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $15 price target. The stock closed at $4.88 on June 29. Acumen is a clinical-stage biopharmaceutical company developing...

June 30, 2022
Celularity
Markets

HCW starts Celularity at buy; PT $15

H.C. Wainwright initiated coverage of Celularity (NASDAQ:CELU) with a “buy” rating and $15 price target. The stock closed at $3.78 on June 21. Celularity is a clinical-stage biopharmaceutical company focused on...

June 22, 2022
Kymera Logo
Markets

Brookline ups Kymera Therapeutics PT to $93 from $80

Brookline Capital Markets raised its price target for Kymera Therapeutics (NASDAQ:KYMR) to $93 from $80 after the company dosed the first patients in separate Phase 1 studies for its KT-333 and KT-413 product candidates...

June 21, 2022
Medivir AB Logo
Markets

Maxim starts Medivir at buy; PT $3

Maxim Group initiated coverage of Sweden-based Medivir AB (OMX:MVIR-B) with a “buy” rating and $3 price target. The stock closed at 77 cents on June 16. Medivir is developing MIV-818 (fostrox), a prodrug of the...

June 17, 2022
ABVC BioPharma Logo
Markets

Maxim starts ABVC BioPharma at buy; PT $3

Maxim Group initiated coverage of ABVC BioPharma (NASDAQ:ABVC) with a “buy” rating and price target of $3. The stock closed at 96 cents on June 16. ABVC is developing assets in ophthalmology, mental health, and oncology...

June 17, 2022
Virpax Pharmaceuticals
Markets

Maxim starts Virpax at buy; PT $4

Maxim Group initiated coverage of Virpax Pharmaceuticals (NASDAQ:VRPX) with a “buy” rating and price target of $4. The stock closed at $1.55 on June 8. Virpax is a diversified pre-clinical stage company developing non...

June 9, 2022
Selecta Biosciences
Markets

SVB starts Selecta Biosciences at OP; PT $7

SVB Securities initiated coverage of Selecta Biosciences (NASDAQ:SELB) with an “outperform” rating and $7 price target. The stock closed at 88 cents on June 3. Selecta is a clinical-stage biotech company advancing its...

June 6, 2022